Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on December 17, 2019. The filing serves to report a material change to the U.S. Securities and Exchange Commission and is incorporated by reference into the company's Registration Statement on Form F-10 (File No. 333-222413).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural filing referencing an external exhibit rather than a financial statement.
Material Changes
The primary material change reported is an underwritten public offering, as detailed in the attached Material Change Report (Exhibit 99.1). The filing itself does not contain the specific terms, volume, or pricing of this offering.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors. These details are expected to be contained within the referenced Exhibit 99.1.
Investor Verification Checklist
- Verify the specific terms, size, and pricing of the underwritten public offering described in Exhibit 99.1.
- Confirm the status and details of the Registration Statement on Form F-10 (File No. 333-222413) into which this report is incorporated.
- Review the full Material Change Report dated December 17, 2019, for details on the capital raise not present in this summary.